<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03082209</url>
  </required_header>
  <id_info>
    <org_study_id>M15-913</org_study_id>
    <secondary_id>2016-003887-37</secondary_id>
    <nct_id>NCT03082209</nct_id>
  </id_info>
  <brief_title>A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies</brief_title>
  <official_title>An Open-Label, Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects With Previously-Treated Solid Tumors and Hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, Phase I, dose-escalation study to determine the maximum tolerated dose
      (MTD) and/or recommended phase two dose (RPTD), and evaluate the safety, efficacy, and
      pharmacokinetic (PK) profile of ABBV-621 for participants with previously-treated solid
      tumors or hematologic malignancies.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 20, 2017</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D) for ABBV-621</measure>
    <time_frame>Up to 21 days</time_frame>
    <description>The MTD and/or RP2D of ABBV-621 will be determined during the dose escalation phase of the study of ABBV-621</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum/plasma concentration time curve (AUC) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Area under the serum/plasma concentration time curve (AUC) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the serum/plasma concentration time curve (AUC) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Area under the serum/plasma concentration time curve (AUC) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum observed serum concentration (Cmax) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Maximum observed serum concentration (Cmax) of venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Time to Cmax (Tmax) of ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to Cmax (Tmax) of Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Time to Cmax (Tmax) of ventoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β) for ABBV-621</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination rate constant (β) for ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination rate constant (β) for Venetoclax</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination rate constant (β) for venetoclax.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of ABBV-621 in Plasma</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination half-life (t1/2) for ABBV-621.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal Phase Elimination Half-life (t1/2) of Venetoclax in Plasma</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>Terminal phase elimination half-life (t1/2) for venetoclax.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>QTcF Change from Baseline</measure>
    <time_frame>Up to 64 days</time_frame>
    <description>QT interval measurement corrected by Fridericia's formula (QTcF) mean change from baseline by dose level</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 42 days after first day of study drug administration or 14 days after bone marrow biopsy showing &lt; 5% blast count (whichever is later)</time_frame>
    <description>Dose limiting toxicities for dose escalation purposes will be determined on events that occur during the first 21-day cycle (with protocol specified exceptions for AML participants).</description>
  </secondary_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Anticipated">205</enrollment>
  <condition>Advanced Solid Tumors</condition>
  <condition>Cancer</condition>
  <condition>Hematologic Malignancies</condition>
  <arm_group>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ABBV-621 via intravenous administration at escalating dose levels in participants with solid tumors including Non-Hodgkin Lymphoma (NHL).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with colorectal cancer (CRC) will be treated with single-agent ABBV-621 to enable selection of the RP2D.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with pancreatic cancer will be treated with single-agent ABBV-621 to enable selection of the recommended Phase 2 dose (RP2D).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with diffuse large B-cell lymphoma (DLBCL) will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 Monotherapy for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with Acute Myeloid Leukemia (AML) will be treated with ABBV-621 monotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Additional participants with AML will be enrolled and will be treated with a combination of ABBV-621 and venetoclax.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with RAS-mutant CRC who have received one prior line of therapy will be administered ABBV-621 in combination FOLFIRI.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with KRAS-mutant CRC are administered with ABBV-621 in combination with bevacizumab plus FOLFIRI</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABBV-621</intervention_name>
    <description>Intravenous (IV)</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
    <arm_group_label>Dose Escalation</arm_group_label>
    <arm_group_label>Dose Optimization for KRAS-mutant CRC</arm_group_label>
    <arm_group_label>Dose Optimization for Pancreatic Cancer</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 Monotherapy for AML</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venetoclax</intervention_name>
    <description>tablet, oral</description>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for AML</arm_group_label>
    <arm_group_label>Dose Optimization: ABBV-621 + Venetoclax for DLBCL</arm_group_label>
    <other_name>ABT-199</other_name>
    <other_name>GDC-0199</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI</intervention_name>
    <description>IV infusion</description>
    <arm_group_label>Chemotherapy combination: ABBV-621 + FOLFIRI + Bevacizumab</arm_group_label>
    <arm_group_label>Chemotherapy combination: ABBV-621+FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must have a diagnosis of a solid tumor (except primary brain tumors), acute myeloid
             leukemia (AML), or non-Hodgkin lymphoma (NHL); NHL may be of any subtype for Dose
             Escalation but is limited to diffuse large B-cell lymphoma (DLBCL) for those enrolled
             to the cohort evaluating the combination of ABBV-621 and venetoclax. Participants in
             the Dose Optimization solid tumor cohorts must have either colorectal cancer with
             documented KRAS mutations (as determined by local testing), or pancreatic cancer
             (irrespective of mutational status). Participants in the chemotherapy combination
             cohorts must have metastatic or advanced unresectable colorectal cancer with
             documented RAS mutations (as determined by local testing).

          -  Participant in dose escalation or dose optimization cohort must have received at least
             one prior systemic therapy, and must have relapsed or progressed after, or failed to
             respond to any/all available effective therapy or therapies.

          -  Participant in chemotherapy cohorts with CRC must have progressed after or failed to
             respond to initial systemic therapy.

          -  Must have measurable disease (by Response Evaluation Criteria In Solid Tumors [RECIST]
             1.1 for those with solid tumors; by Lugano classification for those with NHL), except
             those with AML, who must have histologically confirmed relapsed or refractory disease.

          -  Must agree to provide the following samples for biomarker analysis:

               -  All participants: archived tumor tissue (if available).

               -  Participants in Dose Optimization (excluding AML): pre- and on-treatment fresh
                  tissue biopsies. (Note: fresh tissue biopsies will be optional for participants
                  with solid tumor or NHL in Dose Escalation and will be collected only if consent
                  is provided)

               -  All participants with AML: pre- and on-treatment bone marrow aspirates (BMA)

               -  Participants in chemotherapy combination cohorts: participants must provide a
                  fresh biopsy if an archival biopsy is not available

          -  Participant in chemotherapy cohorts with CRC must have confirmed RAS mutation

          -  Must have an Eastern Cooperative Oncology Group (ECOG) Performance Score of 0 - 2.
             Participants in chemotherapy combination cohorts must have ECOG Performance Score of 0
             - 1.

          -  Must have adequate hematologic, renal and hepatic function.

        Exclusion Criteria:

          -  Participants with history of brain metastases who have not shown clinical and
             radiographic stable disease for at least 28 days after definitive therapy. In
             addition, any AML participant identified through cerebrospinal fluid (CSF) analysis,
             as having active central nervous system (CNS) disease, will be excluded.

          -  Presence of primary hepatobiliary malignancy, including cholangiocarcinoma or
             hepatocellular carcinoma, gallbladder carcinoma, cancer of ampulla of Vater.

          -  Receipt of any systemic anti-cancer agent, including investigational anti-cancer
             products, within 21 days prior to study drug administration or 3 half-lives, whichever
             is longer.

          -  Participant with a history of cirrhosis or other indication of significant possible
             hepatic dysfunction. Note: Those with non-alcoholic steatohepatitis (NASH) should be
             discussed with the AbbVie TA MD before enrollment.

          -  Participant with a positive diagnosis of hepatitis A, B, or C.

          -  Dose Optimization combination cohorts only: Prior receipt, at any time, of a BCL-2
             inhibitor

          -  Dose Optimization combination cohorts only: Participant has received strong or
             moderate CYP3A inhibitors or inducers within 7 days prior to the initiation of study
             treatment.

          -  Dose Optimization combination cohorts only: Participant has malabsorption syndrome or
             other condition that precludes enteral route of administration.

          -  Dose Optimization combination cohorts only: Participant has promyelocytic leukemia
             (M3).

          -  CRC chemotherapy cohort only: Participant with minor surgical procedures, such as fine
             needle aspirations or core biopsies, within 7 days prior to first dose of study drug
             are excluded.

          -  Participants in CRC chemotherapy combination cohort only: cardiomyopathy,
             coronary/peripheral artery bypass graft, aneurysm or aneurysm repair, angioplasty,
             pulmonary hypertension, cerebrovascular accident or transient ischemic attack, within
             1 year of first dose of study drug.

          -  Chemotherapy combination CRC participants only: Prior receipt of an irinotecan-based
             chemotherapy.

          -  Chemotherapy combination CRC participants only: Disease progression within 3-months of
             initiating first-line therapy.

          -  Chemotherapy combination CRC participants only: history of Gilbert's syndrome or
             UG1T1A1 genotypes.

          -  Chemotherapy combination with bevacizumab participants only: clinically significant
             conditions that may place the participant at higher risk with anti-angiogenic therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AbbVie Inc.</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>ABBVIE CALL CENTER</last_name>
    <phone>847.283.8955</phone>
    <email>abbvieclinicaltrials@abbvie.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Yale University /ID# 158029</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago /ID# 158030</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637-1443</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Ingalls Memorial Hosp /ID# 171221</name>
      <address>
        <city>Harvey</city>
        <state>Illinois</state>
        <zip>60426</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Illinois Cancer Care, PC /ID# 214998</name>
      <address>
        <city>Peoria</city>
        <state>Illinois</state>
        <zip>61615</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Univ Michigan Med Ctr /ID# 207134</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital /ID# 171157</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Univ Med Ctr /ID# 215000</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-0011</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center /ID# 202187</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Millennium Oncology /ID# 214981</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77090-1243</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics /ID# 160574</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin /ID# 171152</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226-3522</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East /ID# 160596</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba</state>
        <zip>277-8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Yamagata University Hospital /ID# 200681</name>
      <address>
        <city>Yamagata-shi</city>
        <state>Yamagata</state>
        <zip>990-9585</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen /ID# 169748</name>
      <address>
        <city>Groningen</city>
        <zip>9713 GZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum /ID# 214935</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Erasmus Medisch Centrum /ID# 160869</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Utrecht /ID# 169747</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Vall D'Hebron /ID# 170809</name>
      <address>
        <city>Barcelona</city>
        <zip>08035</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Hospital Fundacion Jimenez Dia /ID# 200106</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosp Univ Madrid Sanchinarro /ID# 165136</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 14, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2017</study_first_posted>
  <last_update_submitted>April 20, 2020</last_update_submitted>
  <last_update_submitted_qc>April 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Solid Tumors</keyword>
  <keyword>Hematologic Malignancies</keyword>
  <keyword>Cancer</keyword>
  <keyword>non-Hodgkin lymphoma</keyword>
  <keyword>acute myeloid leukemia (AML)</keyword>
  <keyword>colorectal cancer (CRC)</keyword>
  <keyword>Diffuse Large B-Cell Lymphoma (DLBCL)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Venetoclax</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

